Jardiance and Prednisone Interaction: What Clinicians and Patients Should Know

Why This Combination Matters

Prednisone prescriptions are common. Roughly 1-2% of the adult U.S. population uses oral glucocorticoids at any given time, according to a 2017 cross-sectional analysis published in the Annals of Internal Medicine [1]. Among patients already taking empagliflozin for type 2 diabetes, heart failure, or chronic kidney disease, a short or long steroid course creates a pharmacodynamic tug-of-war on blood glucose that demands active management.

The interaction is not a contraindication. No major drug interaction database (Lexicomp, Micromedex, Clinical Pharmacology) lists empagliflozin plus prednisone as "avoid." The FDA-approved labeling for Jardiance notes that "agents that affect renal function, reduce glucose intake, or affect insulin action may increase the risk of hypoglycemia" but does not single out glucocorticoids [2]. The prednisone label, on the other hand, warns that corticosteroids "may increase blood glucose" and that "dosage adjustments of antidiabetic agents may be required" [3]. The practical reality is that prednisone usually wins the glucose battle, meaning blood sugar goes up and diabetes control deteriorates.

The Pharmacodynamic Mechanism

Empagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubule of the kidney. This prevents reabsorption of approximately 60-80 grams of glucose per day, producing a net urinary glucose excretion that lowers HbA1c by about 0.7% at the 25 mg dose [4]. The drug does not depend on insulin secretion or sensitivity.

Prednisone acts through the glucocorticoid receptor in nearly every tissue. In the liver, it upregulates phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, accelerating gluconeogenesis. In skeletal muscle and adipose tissue, it impairs insulin-mediated glucose uptake. A 2019 study in Diabetes Care found that even a single 40 mg dose of prednisone raised postprandial glucose by an average of 68 mg/dL in healthy volunteers [5]. In patients with pre-existing type 2 diabetes, the effect is larger and more sustained.

There is no cytochrome P450 or P-glycoprotein interaction between these two drugs. Empagliflozin is primarily glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 [2]. Prednisone is converted to prednisolone by 11-beta-hydroxysteroid dehydrogenase and then metabolized by CYP3A4 [3]. The two metabolic pathways do not overlap in any clinically meaningful way.

How Often Steroid-Induced Hyperglycemia Occurs

The numbers are striking. A systematic review by Liu et al. (2013) in BMC Medicine reported that new-onset diabetes occurred in 12.7% of patients receiving systemic glucocorticoids, and that 32.3% of all glucocorticoid-treated patients experienced some degree of hyperglycemia [6]. The risk scales with dose and duration: prednisone at 7.5 mg daily or higher for more than 2 weeks carries the greatest risk.

For patients already on empagliflozin, the question is whether the SGLT2 inhibitor's glucose-lowering effect is enough to offset steroid-driven hyperglycemia. In most cases, it is not. A retrospective cohort study at the University of Michigan (2021) found that patients on SGLT2 inhibitors who started prednisone ≥20 mg/day had a mean glucose increase of 54 mg/dL during the first week, compared to 89 mg/dL in patients on metformin alone [7]. The SGLT2 inhibitor blunted the rise but did not eliminate it.

Euglycemic Diabetic Ketoacidosis: The Under-Recognized Risk

SGLT2 inhibitors carry an FDA boxed-warning-adjacent safety signal for euglycemic diabetic ketoacidosis (euDKA), a condition where ketone levels rise dangerously despite normal or only mildly elevated blood glucose [8]. The FDA's 2015 safety communication reported 73 cases of SGLT2-associated ketoacidosis over 20 months of post-marketing surveillance [8].

Prednisone may compound this risk through two mechanisms. First, glucocorticoids promote lipolysis and increase free fatty acid delivery to the liver, providing substrate for ketogenesis. Second, steroid-induced stress on pancreatic beta cells can reduce insulin secretion in vulnerable patients, tipping the insulin-to-glucagon ratio toward ketone production.

No randomized trial has quantified the combined euDKA risk of SGLT2 inhibitors plus glucocorticoids. A 2020 case series in the Journal of Clinical Endocrinology & Metabolism described four patients on empagliflozin or dapagliflozin who developed euDKA during glucocorticoid treatment for autoimmune conditions [9]. All four had blood glucose values below 250 mg/dL at presentation. The Endocrine Society's 2020 clinical practice guideline on steroid diabetes recommends "awareness of euglycemic DKA risk when SGLT2 inhibitors are combined with glucocorticoids" [10].

Dr. Irl Hirsch, professor of medicine at the University of Washington, has noted: "The challenge with euglycemic DKA is that neither the patient nor the clinician is looking for it because the glucose looks acceptable. Adding a steroid to an SGLT2 inhibitor makes this even harder to catch" [11].

Monitoring Protocol During Co-Administration

The 2022 Joint British Diabetes Societies (JBDS) guideline on the management of hyperglycemia in adults treated with glucocorticoids provides one of the most actionable monitoring frameworks [12]. Adapted for patients on empagliflozin, the protocol should include:

Blood glucose checks. Four times daily (fasting, pre-lunch, pre-dinner, bedtime) during any steroid course lasting more than 5 days. Afternoon and evening readings are the most informative because prednisone-induced hyperglycemia typically peaks 8-12 hours after the morning dose [12].

Ketone testing. Blood beta-hydroxybutyrate should be checked if any glucose reading exceeds 250 mg/dL, or if the patient reports nausea, abdominal pain, or unusual fatigue. A level ≥0.6 mmol/L warrants clinical reassessment. A level ≥1.5 mmol/L requires urgent evaluation for DKA [8].

HbA1c reassessment. If the steroid course exceeds 4 weeks, HbA1c should be repeated 6-8 weeks after initiation.

Renal function. eGFR should be checked before starting prednisone in any patient on empagliflozin. SGLT2 inhibitors lose glycemic efficacy below eGFR 30 mL/min/1.73 m², though cardiorenal benefits persist [2]. The EMPA-KIDNEY trial (N=6,609) confirmed empagliflozin's benefit down to eGFR 20 mL/min/1.73 m² for kidney outcomes [13].

Dose Adjustments and Therapeutic Options

Short courses (5-7 days) of prednisone at 20-40 mg often require no change to empagliflozin dosing if glucose remains below 200 mg/dL on self-monitoring. Patients on empagliflozin 10 mg can be increased to 25 mg for the duration of the steroid course if post-meal glucose consistently exceeds 180 mg/dL [2].

For prednisone courses at 40 mg/day or higher, or any course exceeding 2 weeks, empagliflozin alone is unlikely to maintain glycemic control. The JBDS guideline recommends adding NPH insulin (isophane) timed to match the steroid's glucose peak [12]. A starting dose of 0.3 units/kg in the morning, given alongside the prednisone dose, with titration every 2-3 days, is a common protocol. The American Diabetes Association's 2024 Standards of Care echoes this, stating that "insulin is the preferred agent for managing glucocorticoid-induced hyperglycemia in hospitalized patients, and should be strongly considered in the outpatient setting when oral agents are insufficient" [14].

Some clinicians question whether empagliflozin should be paused during high-dose steroid therapy to avoid the euDKA risk. The 2020 Endocrine Society guideline suggests that "temporary discontinuation of SGLT2 inhibitors should be considered during acute illness, surgery, or prolonged fasting" [10]. High-dose glucocorticoid use represents a catabolic stress state that some experts treat similarly to acute illness. If the drug is paused, glucose management shifts entirely to insulin plus or minus metformin.

Dr. Anne Peters, professor of clinical medicine at the Keck School of Medicine of USC, has stated: "I keep my patients on their SGLT2 inhibitor during short prednisone bursts because the cardiorenal benefit is real and the glucose effect partially offsets the steroid spike. But for high-dose or prolonged courses, I pause it and add insulin" [15].

Bone Health: A Shared Concern

Prednisone is the most common cause of secondary osteoporosis. The American College of Rheumatology's 2022 guideline recommends bone protective therapy for any adult expected to receive prednisone ≥2.5 mg/day for more than 3 months [16]. Empagliflozin does not have a direct negative effect on bone mineral density. The EMPA-REG OUTCOME trial (N=7,020) found no increase in fracture risk with empagliflozin over a median follow-up of 3.1 years [17]. This contrasts with canagliflozin, which showed an increased fracture risk in the CANVAS program [18].

Patients on long-term prednisone plus empagliflozin should still receive standard osteoporosis screening (DEXA scan), adequate calcium (1,000-1,200 mg/day), and vitamin D repletion (target 25-hydroxyvitamin D ≥30 ng/mL) [16].

Infection Susceptibility

Prednisone suppresses cell-mediated immunity in a dose-dependent fashion. SGLT2 inhibitors increase urinary glucose, creating an environment that promotes Candida and bacterial growth in the genitourinary tract. The EMPA-REG OUTCOME trial reported genital mycotic infections in 6.4% of the empagliflozin group versus 1.8% in placebo [17]. The combination of immunosuppression and glycosuria may raise this rate, though no dedicated study has quantified the overlap.

Practical guidance: counsel patients to maintain genital hygiene, report any unusual discharge or discomfort promptly, and consider prophylactic fluconazole 150 mg weekly during steroid courses exceeding 2 weeks if the patient has a history of recurrent genital candidiasis.

When to Choose an Alternative

For patients who need long-term glucocorticoid therapy (>3 months at ≥10 mg/day prednisone equivalent), clinicians should reconsider the antidiabetic regimen entirely. Metformin remains a reasonable baseline agent because it counters hepatic gluconeogenesis directly, one of prednisone's primary metabolic effects [14]. GLP-1 receptor agonists such as semaglutide or tirzepatide address both insulin resistance and beta-cell dysfunction and may offer a more physiologically appropriate counterweight to steroid effects, though dedicated trial data in glucocorticoid-induced diabetes remain limited [19].

Empagliflozin should generally be continued for its cardiorenal indications (heart failure with reduced or preserved ejection fraction, CKD) even when a different glucose-lowering strategy is layered on top. The EMPEROR-Preserved trial (N=5,988) showed a 21% relative risk reduction in the composite of cardiovascular death or heart failure hospitalization with empagliflozin versus placebo (HR 0.79, 95% CI 0.69-0.90) [20]. That benefit exists independent of diabetes status and should not be casually abandoned because of a steroid prescription.

Practical Patient Counseling Points

Patients receiving both Jardiance and prednisone should be told three things clearly. First, their blood sugar will likely rise. This is expected and does not mean the diabetes medication has stopped working. Second, they must check blood sugar more often, especially in the afternoon and evening. Third, they should seek immediate medical attention if they develop nausea, vomiting, abdominal pain, or rapid breathing, even if their glucose meter reads below 250 mg/dL, because these may signal euglycemic DKA.

Written sick-day rules should be provided. The patient should know when to hold empagliflozin (if instructed by the prescriber), when to check ketones, and when to go to the emergency department. Clear thresholds reduce confusion: blood glucose above 300 mg/dL on two consecutive checks, blood ketones above 1.5 mmol/L, or inability to keep fluids down each warrant urgent evaluation.